155 related articles for article (PubMed ID: 23344238)
1. Targeted siRNA Delivery and mRNA Knockdown Mediated by Bispecific Digoxigenin-binding Antibodies.
Schneider B; Grote M; John M; Haas A; Bramlage B; Ickenstein LM; Jahn-Hofmann K; Bauss F; Cheng W; Croasdale R; Daub K; Dill S; Hoffmann E; Lau W; Burtscher H; Ludtke JL; Metz S; Mundigl O; Neal ZC; Scheuer W; Stracke J; Herweijer H; Brinkmann U
Mol Ther Nucleic Acids; 2012 Sep; 1(9):e46. PubMed ID: 23344238
[TBL] [Abstract][Full Text] [Related]
2. Bispecific digoxigenin-binding antibodies for targeted payload delivery.
Metz S; Haas AK; Daub K; Croasdale R; Stracke J; Lau W; Georges G; Josel HP; Dziadek S; Hopfner KP; Lammens A; Scheuer W; Hoffmann E; Mundigl O; Brinkmann U
Proc Natl Acad Sci U S A; 2011 May; 108(20):8194-9. PubMed ID: 21536919
[TBL] [Abstract][Full Text] [Related]
3. Bispecific Antibodies for Targeted Delivery of Dendritic Polyglycerol (dPG) Prodrug Conjugates.
Mehrabadi FS; Adelmann J; Gupta S; Wedepohl S; Calderón M; Brinkmann U; Haag R
Curr Cancer Drug Targets; 2016; 16(7):639-49. PubMed ID: 26853135
[TBL] [Abstract][Full Text] [Related]
4. Hapten-Binding Bispecific Antibodies for the Targeted Delivery of SiRNA and SiRNA-Containing Nanoparticles.
Thorey IS; Grote M; Mayer K; Brinkmann U
Methods Mol Biol; 2016; 1364():219-34. PubMed ID: 26472454
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
[TBL] [Abstract][Full Text] [Related]
6. Efficient and Highly Specific Gene Transfer Using Mutated Lentiviral Vectors Redirected with Bispecific Antibodies.
Parker CL; Jacobs TM; Huckaby JT; Harit D; Lai SK
mBio; 2020 Jan; 11(1):. PubMed ID: 31964730
[TBL] [Abstract][Full Text] [Related]
7. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
8. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
[TBL] [Abstract][Full Text] [Related]
9. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
10. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
[TBL] [Abstract][Full Text] [Related]
11. GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma.
Park JA; Cheung NV
J Hematol Oncol; 2020 Dec; 13(1):172. PubMed ID: 33303017
[TBL] [Abstract][Full Text] [Related]
12. Opportunities and challenges of bi-specific antibodies.
Segués A; Huang S; Sijts A; Berraondo P; Zaiss DM
Int Rev Cell Mol Biol; 2022; 369():45-70. PubMed ID: 35777864
[TBL] [Abstract][Full Text] [Related]
13. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
14. Binary and ternary complexes based on polycaprolactone-graft-poly (N, N-dimethylaminoethyl methacrylate) for targeted siRNA delivery.
Huang Y; Lin D; Jiang Q; Zhang W; Guo S; Xiao P; Zheng S; Wang X; Chen H; Zhang HY; Deng L; Xing J; Du Q; Dong A; Liang Z
Biomaterials; 2012 Jun; 33(18):4653-64. PubMed ID: 22480869
[TBL] [Abstract][Full Text] [Related]
15. Delivery of gene targeting siRNAs to breast cancer cells using a multifunctional peptide complex that promotes both targeted delivery and endosomal release.
Bjorge JD; Pang A; Fujita DJ
PLoS One; 2017; 12(6):e0180578. PubMed ID: 28666009
[TBL] [Abstract][Full Text] [Related]
16. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.
Khare P; Dave KM; Kamte YS; Manoharan MA; O'Donnell LA; Manickam DS
AAPS J; 2021 Dec; 24(1):8. PubMed ID: 34873640
[TBL] [Abstract][Full Text] [Related]
17. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.
Schoonjans R; Willems A; Schoonooghe S; Leoen J; Grooten J; Mertens N
Biomol Eng; 2001 Jun; 17(6):193-202. PubMed ID: 11337278
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
[TBL] [Abstract][Full Text] [Related]
19. Lipid Nanoparticle Formulations for Enhanced Co-delivery of siRNA and mRNA.
Ball RL; Hajj KA; Vizelman J; Bajaj P; Whitehead KA
Nano Lett; 2018 Jun; 18(6):3814-3822. PubMed ID: 29694050
[TBL] [Abstract][Full Text] [Related]
20. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
